T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a
heterogeneous clinical course. With the advent of novel treatment options that will potentially …

Leukemia cutis (LC) is a nonspecific term used for cutaneous manifestations of any type of
leukemia. LC has a wide range of cutaneous manifestations, which can make it difficult to …

Most consensus leukemia & lymphoma antibody panels consist of lists of markers based on
expert opinions, but they have not been validated. Here we present the validated EuroFlow …

T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature T-cell
malignancy. Here we integrated large-scale profiling data of alterations in gene expression …

Distinguishing blastic plasmacytoid dendritic cell neoplasm (BPDCN) from acute myeloid
leukemia (AML) is gaining increased importance because of emerging differences in …

T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive neoplasm of mature T-cells
with an urgent need for rationally designed therapies to address its notoriously chemo …

Expression of the human oncogene TCL1 in transgenic mice produces B-cell tumors that
resemble chronic lymphocytic leukemia (CLL) suggesting its role in B-cell tumorigenesis. To …

Described herein is the evolution in the diagnosis and classification of tumors that are
variously known as blastic or blastoid natural killer cell lymphoma, CD4+/CD56+ …

T-prolymphocytic leukemia (T-PLL) is a rare T-cell neoplasm with an aggressive clinical
course. Leukemic T-cells exhibit a post-thymic T-cell phenotype (Tdt−, CD1a−, CD5+, CD2+ …

The T-cell leukemia 1 (TCL1) oncoprotein is overexpressed by chromosomal rearrangement
in the majority of cases of T-cell prolymphocytic leukemia (T-PLL). In vitro, TCL1 can …